Nasdaq · Healthcare
Travere Therapeutics, Inc. (TVTX)
As-reported financials and recent SEC filings for Travere Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$490.7M
Net income
$-25.5M
Net margin
-5.2%
Diluted EPS
$-0.29
ROE
-22.2%
P/E (TTM)
—
Market cap
$5.47B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M |
| Gross profit | — | — | — | — | — |
| Operating income | $-62.8M | $-323.8M | $-388.1M | $-319.8M | $-199.4M |
| Net income | $-25.5M | $-321.5M | $-111.4M | $-278.5M | $-180.1M |
| Diluted EPS | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →S-82026-06-17
View on EDGAR →42026-06-16
View on EDGAR →8-K2026-06-16
View on EDGAR →42026-06-16
View on EDGAR →1442026-06-12
View on EDGAR →1442026-06-12
View on EDGAR →8-K2026-06-02
View on EDGAR →Go deeper on TVTX
Search Travere Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.